Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Avexitide

Peptide · Antagonist of glucagon-like peptide-1 receptor (GLP1R) · developed by Amylyx Pharmaceuticals

Phase 3 Most advanced trial

AMLX Developer

1 Registered trials

What is Avexitide?

Avexitide (exendin 9-39) is a 31-amino acid peptide that competitively binds the GLP-1 receptor and inhibits GLP-1 signaling, thereby reducing GLP-1-mediated insulin secretion and glucagon suppression. It is being studied in post-bariatric hypoglycemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: exendin 9-39
Drug type: Peptide
Targets: glucagon-like peptide-1 receptor (GLP1R)
Mechanism: Antagonist of glucagon-like peptide-1 receptor (GLP1R)
Pathways: GLP-1 receptor signaling, GLP-1-mediated insulin secretion, GLP-1-mediated glucagon suppression
Therapy area: Metabolic
Developer: Amylyx Pharmaceuticals Inc. (AMLX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 5313W10MYT

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06747468	Phase 3	Post Bariatric Hypoglycemia	Active not recruiting	AMLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Post Bariatric Hypoglycemia

Other drugs acting on GLP1R

Dulaglutide FDA approved Orforglipron FDA approved Semaglutide FDA approved Tirzepatide FDA approved Maridebart Cafraglutide Phase 3 VK2735 Investigational

More from Amylyx Pharmaceuticals

AMX0035 Phase 2/3 AMX0114 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AMLX page.

Follow AMLX, the company behind Avexitide

See AMLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMLX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z